Artificial intelligence is increasingly integrated into biotechnology, boosting drug design and biomedical research. Researchers at the University of Pennsylvania developed PepMLM, a protein language model enabling design of peptide binders for challenging targets without requiring protein structure data, addressing undruggable proteins. Meanwhile, MIT researchers applied AI to discover compounds effective against drug-resistant bacteria. AI platforms also streamline analytics in pharmaceutical compliance and clinical trial monitoring, highlighting AI’s expanding role in biomedicine.